Transient myeloproliferative disorder and acute myeloid leukemia in Down syndrome: An immunophenotypic analysis

N. J. Karandikar, D. B. Aquino, R. W. McKenna, S. H. Kroft

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Immunophenotypic analysis of transient myeloproliferative disorder (TMD) and acute myeloid leukemia (AML) using multiparameter flow cytometry might provide insight into their relationship. We retrospectively analyzed the expression of multiple lymphoid, myelomonocytic, and megakaryocytic antigens on blast proliferations in 18 patients with Down syndrome (DS; AML, 9; TMD, 9). The AMLs and TMDs shared several immunophenotypic characteristics. Blasts in all expressed CD45, CD38, and CD33; most AMLs and all TMDs were CD36+; and the majority expressed CD41 and CD61, suggesting megakaryocytic differentiation. The majority of cases were CD34+, CD14-, and CD64-. There was aberrant expression of the T-cell-associated antigen CD7 in most AMLs and TMDs. CD56 was expressed aberrantly in 5 AMLs and 7 TMDs. The major difference between the disorders was the pattern of expression of myeloid markers CD11b and CD13; each was expressed in 8 AMLs but only 2 TMDs. Blasts were HLA-DR-positive in 3 AMLs vs 7 TMDs. Blasts in TMD and AML in DS have a characteristic immunophenotype distinct from AML in other settings. The immunophenotypic similarities suggest a biologic relationship between the disorders; however, distinct immunophenotypic differences also were observed.

Original languageEnglish (US)
Pages (from-to)204-210
Number of pages7
JournalAmerican Journal of Clinical Pathology
Volume116
Issue number2
DOIs
StatePublished - 2001

Fingerprint

Myeloproliferative Disorders
Down Syndrome
Acute Myeloid Leukemia
CD7 Antigens
HLA-DR Antigens
Flow Cytometry
T-Lymphocytes
Antigens

Keywords

  • AML
  • Down syndrome
  • Flow cytometry
  • Immunophenotype
  • Leukemia
  • TMD
  • Transient myeloproliferative disorder

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Transient myeloproliferative disorder and acute myeloid leukemia in Down syndrome : An immunophenotypic analysis. / Karandikar, N. J.; Aquino, D. B.; McKenna, R. W.; Kroft, S. H.

In: American Journal of Clinical Pathology, Vol. 116, No. 2, 2001, p. 204-210.

Research output: Contribution to journalArticle

Karandikar, N. J. ; Aquino, D. B. ; McKenna, R. W. ; Kroft, S. H. / Transient myeloproliferative disorder and acute myeloid leukemia in Down syndrome : An immunophenotypic analysis. In: American Journal of Clinical Pathology. 2001 ; Vol. 116, No. 2. pp. 204-210.
@article{25862a244f3d44388330e6681ee13c81,
title = "Transient myeloproliferative disorder and acute myeloid leukemia in Down syndrome: An immunophenotypic analysis",
abstract = "Immunophenotypic analysis of transient myeloproliferative disorder (TMD) and acute myeloid leukemia (AML) using multiparameter flow cytometry might provide insight into their relationship. We retrospectively analyzed the expression of multiple lymphoid, myelomonocytic, and megakaryocytic antigens on blast proliferations in 18 patients with Down syndrome (DS; AML, 9; TMD, 9). The AMLs and TMDs shared several immunophenotypic characteristics. Blasts in all expressed CD45, CD38, and CD33; most AMLs and all TMDs were CD36+; and the majority expressed CD41 and CD61, suggesting megakaryocytic differentiation. The majority of cases were CD34+, CD14-, and CD64-. There was aberrant expression of the T-cell-associated antigen CD7 in most AMLs and TMDs. CD56 was expressed aberrantly in 5 AMLs and 7 TMDs. The major difference between the disorders was the pattern of expression of myeloid markers CD11b and CD13; each was expressed in 8 AMLs but only 2 TMDs. Blasts were HLA-DR-positive in 3 AMLs vs 7 TMDs. Blasts in TMD and AML in DS have a characteristic immunophenotype distinct from AML in other settings. The immunophenotypic similarities suggest a biologic relationship between the disorders; however, distinct immunophenotypic differences also were observed.",
keywords = "AML, Down syndrome, Flow cytometry, Immunophenotype, Leukemia, TMD, Transient myeloproliferative disorder",
author = "Karandikar, {N. J.} and Aquino, {D. B.} and McKenna, {R. W.} and Kroft, {S. H.}",
year = "2001",
doi = "10.1309/XREF-C9T2-6U0A-4EDT",
language = "English (US)",
volume = "116",
pages = "204--210",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "2",

}

TY - JOUR

T1 - Transient myeloproliferative disorder and acute myeloid leukemia in Down syndrome

T2 - An immunophenotypic analysis

AU - Karandikar, N. J.

AU - Aquino, D. B.

AU - McKenna, R. W.

AU - Kroft, S. H.

PY - 2001

Y1 - 2001

N2 - Immunophenotypic analysis of transient myeloproliferative disorder (TMD) and acute myeloid leukemia (AML) using multiparameter flow cytometry might provide insight into their relationship. We retrospectively analyzed the expression of multiple lymphoid, myelomonocytic, and megakaryocytic antigens on blast proliferations in 18 patients with Down syndrome (DS; AML, 9; TMD, 9). The AMLs and TMDs shared several immunophenotypic characteristics. Blasts in all expressed CD45, CD38, and CD33; most AMLs and all TMDs were CD36+; and the majority expressed CD41 and CD61, suggesting megakaryocytic differentiation. The majority of cases were CD34+, CD14-, and CD64-. There was aberrant expression of the T-cell-associated antigen CD7 in most AMLs and TMDs. CD56 was expressed aberrantly in 5 AMLs and 7 TMDs. The major difference between the disorders was the pattern of expression of myeloid markers CD11b and CD13; each was expressed in 8 AMLs but only 2 TMDs. Blasts were HLA-DR-positive in 3 AMLs vs 7 TMDs. Blasts in TMD and AML in DS have a characteristic immunophenotype distinct from AML in other settings. The immunophenotypic similarities suggest a biologic relationship between the disorders; however, distinct immunophenotypic differences also were observed.

AB - Immunophenotypic analysis of transient myeloproliferative disorder (TMD) and acute myeloid leukemia (AML) using multiparameter flow cytometry might provide insight into their relationship. We retrospectively analyzed the expression of multiple lymphoid, myelomonocytic, and megakaryocytic antigens on blast proliferations in 18 patients with Down syndrome (DS; AML, 9; TMD, 9). The AMLs and TMDs shared several immunophenotypic characteristics. Blasts in all expressed CD45, CD38, and CD33; most AMLs and all TMDs were CD36+; and the majority expressed CD41 and CD61, suggesting megakaryocytic differentiation. The majority of cases were CD34+, CD14-, and CD64-. There was aberrant expression of the T-cell-associated antigen CD7 in most AMLs and TMDs. CD56 was expressed aberrantly in 5 AMLs and 7 TMDs. The major difference between the disorders was the pattern of expression of myeloid markers CD11b and CD13; each was expressed in 8 AMLs but only 2 TMDs. Blasts were HLA-DR-positive in 3 AMLs vs 7 TMDs. Blasts in TMD and AML in DS have a characteristic immunophenotype distinct from AML in other settings. The immunophenotypic similarities suggest a biologic relationship between the disorders; however, distinct immunophenotypic differences also were observed.

KW - AML

KW - Down syndrome

KW - Flow cytometry

KW - Immunophenotype

KW - Leukemia

KW - TMD

KW - Transient myeloproliferative disorder

UR - http://www.scopus.com/inward/record.url?scp=0034764037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034764037&partnerID=8YFLogxK

U2 - 10.1309/XREF-C9T2-6U0A-4EDT

DO - 10.1309/XREF-C9T2-6U0A-4EDT

M3 - Article

C2 - 11488066

AN - SCOPUS:0034764037

VL - 116

SP - 204

EP - 210

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 2

ER -